<?xml version="1.0" encoding="UTF-8"?>
<p>In addition, CEPI will provide support with respect to the clinical development of vaccine candidates, as well as in exploring regulatory pathways. The aim is to conduct clinical trials in affected endemic countries as early in the development as possible. CEPI will support the identification of clinical trial sites covering target populations and will engage in capacity building. It cooperates with the Brighton Collaboration, an international network of pharmacovigilance experts, to, among other activities, develop case definitions for potential adverse events of special interest (AESIs), including, for example, sensorineural hearing loss for the safety evaluation of Lassa vaccine candidates [
 <xref ref-type="bibr" rid="CR34">34</xref>]. Moreover, the Brighton Collaboration will provide expertise in program-specific (upon request) and cross-program pharmacovigilance, for example by establishing aÂ metadata safety monitoring board (meta-DSMB).
</p>
